cog1410 and Brain-Infarction

Growing clinical evidence implicates isoform-specific effects of apolipoprotein E (apoE) in reducing neuroinflammation and mediating adaptive responses following ischemic and traumatic brain injury. However, the intact apoE holoprotein does not cross the blood-brain barrier and thus has limited therapeutic potential. We have created a small peptide, COG1410 (acetyl-AS-Aib-LRKL-Aib-KRLL-amide), derived from the apoE receptor-binding region. COG1410 retains the anti-inflammatory and neuroprotective biological properties of the intact holoprotein and penetrates the blood-brain barrier. In the current study, we utilized a murine model of transient focal cerebral ischemia and reperfusion to demonstrate that intravenous (IV) administration of COG1410 reduces infarct volume and radiographic progression of infarct, and improves functional outcome as assessed by rotarod when delivered up to 4h after ischemia onset.

Topics: Analysis of Variance; Animals; Apolipoproteins E; Brain Edema; Brain Infarction; Chromatography, Liquid; Disease Models, Animal; Encephalitis; Functional Laterality; Gene Expression Regulation; Infarction, Middle Cerebral Artery; Magnetic Resonance Imaging; Male; Mass Spectrometry; Mice; Mice, Inbred C57BL; Movement Disorders; Recovery of Function; RNA, Messenger; Time Factors; Tumor Necrosis Factor-alpha